DevsHealth is a DeepTech company that focuses on drug development for infectious diseases using advanced technology, including AI and molecular modeling.

DevsHealth

Primordial AI utilizes evolutionary data and artificial intelligence to discover drug targets, focusing on achieving next-generation drug development.

Primordial AI

DevsHealth | 645 followers on LinkedIn. At DevsHealth, we leverage our advanced DeepTech platform to enhance the development of anti-infective treatments. | DevsHealth is a pioneering DeepTech company that industrializes drug discovery, transforming it into a scalable endeavor. Our proprietary technology platform, which integrates AI, real-world data (RWD), and molecular modeling, is at the forefront of revolutionizing the development of new anti-infective treatments, including antiviral and antibiotic drugs.

Our platform and business model enable us to streamline the initial stages of drug development, significantly reducing the time, risk, and cost typically associated with traditional methods.

Entrepreneur, teacher and learner

Albert Garcia Pujadas qtorb

COO & Co-Founder at DevsHealth. Seasoned Professional in Pharma, Chemical & Consumer Health. Associate Partner-Advisor at BHV Partners; Mentor &…

Xavier Farrés Torrecabota

Today you can find us at the Barcelona Deep Tech Summit ! Come to our booth in the startups area and learn more about how we are using our DeepTech platform to improve global health by developing new treatments for infectious diseases. #AMR #DeepTech #DeepTechSummit #DrugDiscovery

A few days ago, we shared a post from the World Economic Forum about the urgent need for sustainable financing models to combat antimicrobial resistance (AMR). Today, we want to share our thoughts on this critical issue and highlight the importance of innovative technologies in boosting drug development for infectious diseases. Together, we can turn the tide against AMR and safeguard global health! #AMR #DrugDiscovery #DeepTech https://lnkd.in/dtfh92RN

Antimicrobial resistance (AMR) could cause 10 million deaths and cost $100 trillion by 2050. World leaders have pledged to reduce AMR-related global deaths by 10% by 2030. AMR is accelerated by the misuse and overuse of antimicrobials. The development of new antibiotics is limited due to lack of incentives and innovative financing models needed to drive research and the production of new drugs. in DevsHealth , harnessing the power of AI, advanced data analysis, and cutting-edge molecular modeling, our state-of-the-art DeepTech platform is revolutionizing the development of drugs for infectious diseases. We are changing how new drugs are designed making it scalable and efficient thanks to continous learning and development approach together with cost, time and risk reduction. If you want to stay up-to-date with us, follow our Page.

📢 New Report Alert! 📢 Check out this insightful report from the World Economic Forum on sustainable financing models to combat antimicrobial resistance (AMR). 🌍🦠 The report highlights the growing threat of AMR, which could kill 10 million people and cost health systems $100 trillion by 2050. It also explores innovative financing models that can help tackle this global health crisis. #AMR #GlobalHealth #SustainableFinance #DevsHealth https://lnkd.in/ej_cDBdW

🌟 Celebrating the 2024 Nobel Prize in Chemistry: The Revolution of Computational Biology 🌟 Congratulations to Demis Hassabis and John Jumper from DeepMind, and David Baker from the University of Washington, for winning the 2024 Nobel Prize in Chemistry! Their groundbreaking work in protein structure prediction and computational protein design is a testament to the transformative potential of advanced technologies in science and medicine. 🔬 DevsHealth: At the Forefront of Innovation 🔬 At DevsHealth, we utilize techniques similar to those acknowledged by the Nobel Prize in our DevsHealth OS platform to accelerate the discovery of new treatments for infectious diseases. Our technology allows us to design and test in silico over 10 million compounds in just a few days, reducing drug discovery time from 2-3 years to just 6 months. This approach is not only faster but also more cost-effective, enabling us to test only 10-20 compounds instead of hundreds. 🚀 Current Projects and Promising Future 🚀 We are currently working on innovative projects such as a broad-spectrum treatment for Flavivirus infections and an antimicrobial against multi-resistant Staphylococcus aureus. Additionally, we plan to grow to around 50 simultaneous projects in 4 years, with potential annual revenues of 150-200 million euros from licenses. 🌍 Global Impact 🌍 DevsHealth’s approach can help address global health issues like antimicrobial resistance. The recognition by the Nobel Prize validates our approach and inspires us to continue accelerating the development of vital treatments for global health. #NobelPrize #MolecularModelling #DrugDiscovery https://lnkd.in/er2i5ZTa

We celebrate and welcome the approval of the Political Declaration on antimicrobial resistance (AMR) by United Nations member states during the meeting which took place yesterday, September 26th. Member states declaration can be summarised in a short paragraph: "The research and development pipeline for vaccines, diagnostics, therapeutics, especially antimicrobials and alternatives to the use of antimicrobials, to prevent and address antimicrobial resistance, especially antibiotics, are insufficient". It sounds very good and the list of commitments is amazing. We encourage governments to move forward and start to work on it, mainly in the funding mechanisms as well as to promote and accelerate public-private partnerships. #AMR #Antivirals #InfectiousDiseases #Antibiotics https://lnkd.in/e-PzchgP

🚀 Exciting News from DevsHealth! 🚀 It is a pleasure to announce our strategic partnership with Aragen for the chemical synthesis of our projects. This collaboration marks a significant business milestone for DevsHealth, unlocking new potential in our research and development efforts. This partnership not only enhances our capabilities but also strengthens our ties with India, a powerhouse in the pharmaceutical industry. We look forward to the innovative breakthroughs this collaboration will bring! 🔗 Read more about our partnership #DevsHealth #Pharmaceuticals #Innovation #Partnership #India #infectiousDiseases https://lnkd.in/eEVA8UE4

Congratulations to all Aragen's team. Proud of having you as our chemistry partner!

🔬 Exciting Collaboration Alert! 🌟 We’re thrilled to announce a groundbreaking partnership between DevsHealth and the Germans Trias i Pujol Research Institute (IGTP) . Together, we’re embarking on a mission to develop new antibiotics aimed at combating hospital-acquired infections caused by multi-resistant Staphylococcus aureus. 🧫 Staphylococcus aureus is notorious for causing severe infections and is recognized by the WHO as a high-priority pathogen due to its resistance to existing antibiotics. This collaboration is not just a step forward in medical science; it’s a leap towards safeguarding public health. 💡 By leveraging DevsHealth’s innovative DeepTech platform and IGTP’s extensive bacterial collection, we aim to discover drugs that can outsmart resistance mechanisms. Our combined expertise signifies hope for effective treatments against these formidable infections. 🤝 This partnership aligns perfectly with our vision to industrialize drug development and create the largest pipeline for infectious diseases. It’s a fusion of technology and science where AI meets years of research to fast-track the discovery of life-saving drugs. Stay tuned as we embark on this exciting journey. Together, we can make a difference! #DevsHealth #IGTP #Innovation #Healthcare #Antibiotics #Collaboration #PublicHealth #AMR https://lnkd.in/dBCj_wCK

Big News from DevsHealth! 🚀 We are excited to share that DevsHealth has been certified by Enisa con el emprendimiento innovador , Spain’s national innovation agency. This certification marks a pivotal moment for us: 🌟 Investor Attraction: With ENISA’s certification, DevsHealth stands out as a prime opportunity for investors. Expect enhanced tax incentives and a streamlined process that makes investing in our vision more appealing than ever. 🌐 Welcoming Global Investments: This certification eases the way for foreign investors to contribute to our journey, fostering a global community around our innovative health solutions. ✨ Acknowledgment of Promise: Being recognized by ENISA signifies that DevsHealth is seen as a company with immense promise and potential for growth. It’s a testament to our dedication and forward-thinking approach in the health tech sector. 🎖️ Advantages for Us: Beyond the benefits for investors, this certification provides us with additional advantages, reinforcing our status as a leading innovator in healthcare technology. Let’s celebrate this achievement as we continue to push the boundaries of what’s possible in healthcare. Together, we’re making strides toward a healthier future! #DevsHealth #ENISACertification #HealthTech #Innovation #InvestmentOpportunity

Metric
Company Name	DevsHealth	Primordial AI
Symbol
MSH ID	COM:DEVSHEALTH	COM:PRIMORDIALBIO
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	ES	US
Stage
Employee Count
Website	devshealth.com	primordialbio.com
LinkedIn	devshealth	primordial-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DEVS

COM:DEVSHEALTH

DevsHealth

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue